miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype by Radisky, Derek C
miRNAs are a family of small noncoding RNA molecules 
that downmodulate gene expression through post-
transcriptional mechanisms, and individual miRNAs 
have been found to play critical roles in mammary gland 
development and breast cancer progression. In the 
previous issue of Breast Cancer Research, Howe and 
colleagues ﬁ   nd that miR-200c plays a broader role in 
suppression of breast cancer development than had been 
previously suspected [1]. Members of the miR-200 family 
had previously been investigated for their ability to inhibit 
epithelial–mesenchymal transition (EMT), a develop-
mental process in which epithelial cells acquire the migra-
tory, invasive, and apoptosis-resistant properties of mesen-
chymal cells [2-4]. To date, the most investigated targets 
of miR-200 family members have been the transcription 
factors ZEB1 and ZEB2, regulators of EMT that maintain 
the mesenchymal phenotype by downmodulating expres-
sion of E-cadherin as well as other mediators of epithelial 
cell polarity and function [5]. Previous studies from the 
Richer laboratory, however, have shown that reintro  duc-
tion of miR-200c into Hey ovarian cancer cells led to 
decreased migration and invasion even though E-cad-
herin was not re-expressed [6], suggesting that miR-200c 
could also aﬀ  ect invasion through processes independent 
of the ZEB1/2–E-cadherin axis.
To identify ZEB1-independent mechanisms by which 
miR-200c could inhibit cell motility, Howe and colleagues 
used a panel of breast and endometrial cancer cell lines 
previously identiﬁ   ed as miR-200c deﬁ   cient [1]. MDA-
MB-231 and BT549 breast cancer cells and Hec50 and 
AN3CA endometrial cancer cells express very low levels 
of miR-200c, high levels of ZEB1, and little E-cadherin; 
expression of miR-200c in these cells is suﬃ   cient  to 
inhibit ZEB1 and increase expression of E-cadherin [1,7]. 
Analysis of microarray proﬁ   les of Hec50 endometrial 
cells in which miR-200c had been re-expressed revealed 
several additional genes that were potential targets of 
miR-200c and which had been previously implicated in 
cell motility, including the extracellular matrix protein 
ﬁ  bronectin 1 and the actin-organizing protein moesin. 
Luciferase reporter assays were used to show that miR-
200c directly targeted the 3’ UTR of these genes. While 
expression of miR-200c in these cells led to signiﬁ  cantly 
decreased cell motility and re-expression of E-cadherin, 
further addition of plasmids encoding either ﬁ  bronectin 
1 or moesin that could not be targeted by miR-200c 
restored cellular migratory ability without aﬀ  ecting 
E-cadherin expression levels – eﬀ  ectively demonstrating 
that miR-200c can aﬀ  ect cell motility through both ZEB1/
E-cadherin-dependent and ZEB1/E-cadherin-independent 
pathways.
Another important mesenchymal characteristic that 
can be acquired through activation of the EMT program 
in tumor cells is increased ability to tolerate conditions 
that should trigger apoptotic cell death. Researchers from 
the Richer laboratory had previously shown that re-
expression of miR-200c in breast, endometrial, and 
ovarian cancer cells led to increased susceptibility to 
apoptosis induced by microtubule-targeting chemothera-
peutic agents [7]. In the present study, Howe and 
colleagues identify the neurotrophic receptor tyrosine 
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© 2011 BioMed Central Ltdkinase 2 (which encodes the protein TrkB) as a speciﬁ  c 
target of miR-200c that confers resistance to anoikis [1]. 
Anoikis is the cell death program activated in anchorage-
dependent cells upon separation from the extracellular 
matrix, suppression of which is believed to be a necessary 
step in development of breast ductal carcinoma in situ 
[8]. TrkB was shown to act as a mediator of anoikis 
resistance in both BT549 and Hec50 cells, and restoration 
of miR-200c caused decreased expression of TrkB protein 
concomitant with increased death of cells cultured on 
nonadhesive substrata; resistance to anoikis in the miR-
200c-expressing cells was speciﬁ   cally regained by 
expression of a TrkB construct that could not be targeted 
by miR-200c. Th  ese experiments identify a novel and 
unexpected potential function for miR-200c in blocking 
tumor progression. Intriguingly, recent studies with rat 
kidney epithelial cells have found that ZEB1 is a required 
downstream eﬀ  ector for TrkB-induced anoikis resistance 
[9], and other investigators have found that the miR-200c 
target Fas-associated phophatase 1 is involved in resis-
tance to Fas-mediated apoptosis [10], suggesting that 
miR-200c can also control apoptosis through both ZEB1-
dependent and ZEB1-independent processes.
Induction of the EMT program has also been linked 
with the breast cancer stem cell (CSC) phenotype, 
charac  terized by increased malignant potential and 
resistance to chemotherapeutic agents [11]. A series of 
recent studies have implicated miR-200 family members 
and targets in activation and maintenance of the CSC 
pheno  type, as miR-200c is downregulated in breast 
cancer cells that express CSC markers [12] and re-
expression of miR-200 family members can reverse CSC 
characteristics [12,13]. Furthermore, while ZEB1 and 
ZEB2 were previously shown to target miR-200 family 
members in a self-reinforcing feedback loop [3], recent 
studies have indicated that ZEB1 also inhibits other 
miRNAs involved in stem cell characteristics, including 
miR-203 and miR-183 [14]. It is striking that the key 
characteristics of the CSC phenotype – the ability to 
grow on nonadhesive substrata and increased cell 
motility [15] – are both identiﬁ  ed in the current study as 
being directly regulated by miR-200c [1].
An important consideration when evaluating these 
pathways in cancer cells is that the function of miR-200 
in controlling EMT is likely to be highly dependent upon 
speciﬁ  c characteristics of the developing tumors; indeed, 
the targets of miR-200c identiﬁ   ed by Howe and 
colleagues are not invariably induced in every cell line 
with reduced levels of the miRNA [1]. Unlike develop-
mental EMT, which proceeds as an orchestrated program 
of many diﬀ  erent mediators and eﬀ  ectors to induce an 
organized outcome, the more chaotic tumor micro-
environ  ment can stimulate incomplete or transient 
activation of the EMT program. As activation of even a 
subset of EMT-associated processes may be suﬃ   cient to 
confer increased motility or resistance to apoptotic stimuli 
without complete conversion to a mesenchymal cell, it 
may be necessary for cellular mediators that regu  late EMT 
to be suﬃ   ciently ﬂ  exible to inhibit many diﬀ  er  ent targets – 
a job that is perhaps particularly well suited for miRNA. 
Deﬁ  ning the full range of targets through which miR-200c 
functions as a tumor suppressor could provide insight into 
how (and why) activation of the EMT program in tumors 
is linked to apoptosis resistance and the CSC phenotype, a 
critical question yet to be fully addressed.
Abbreviations
CSC, cancer stem cell; EMT, epithelial–mesenchymal transition; miRNA, 
microRNA; UTR, untranslated region; ZEB, zinc-fi  nger enhancer binding.
Competing interests
The author declares that he has no competing interests.
Published: 10 June 2011
References
1.    Howe EN, Cochrane DR, Richer JK: Targets of miR-200c mediate suppression 
of cell motility and anoikis resistance. Breast Cancer Res 2011, 13:R45.
2.    O’Day E, Lal A: MicroRNAs and their target gene networks in breast cancer. 
Breast Cancer Res 2010, 12:201.
3.    Brabletz S, Brabletz T: The ZEB/miR-200 feedback loop – a motor of cellular 
plasticity in development and cancer? EMBO Rep 2010, 11:670-677.
4.    Wright JA, Richer JK, Goodall GJ: MicroRNAs and EMT in mammary cells and 
breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:213-223.
5.   Peter  ME:  Let-7 and miR-200 microRNAs: guardians against pluripotency 
and cancer progression. Cell Cycle 2009, 8:843-852.
6.    Cochrane DR, Howe EN, Spoelstra NS, Richer JK: Loss of miR-200c: a marker 
of aggressiveness and chemoresistance in female reproductive cancers. 
J Oncol 2010, 2010:821717.
7.    Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK: MicroRNA-200c 
mitigates invasiveness and restores sensitivity to microtubule-targeting 
chemotherapeutic agents. Mol Cancer Ther 2009, 8:1055-1066.
8.    Chiarugi P, Giannoni E: Anoikis: a necessary death program for anchorage-
dependent cells. Biochem Pharmacol 2008, 76:1352-1364.
9.    Smit MA, Peeper DS: Zeb1 is required for TrkB-induced epithelial–
mesenchymal transition, anoikis resistance and metastasis. Oncogene 2011 
[Epub ahead of print].
10  .  Schickel R, Park SM, Murmann AE, Peter ME: miR-200c regulates induction of 
apoptosis through CD95 by targeting FAP-1. Mol Cell 2010, 38:908-915.
11  .  Reiman JM, Knutson KL, Radisky DC: Immune promotion of epithelial–
mesenchymal transition and generation of breast cancer stem cells. 
Cancer Res 2010, 70:3005-3008.
12  .  Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, 
Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF: 
Downregulation of miRNA-200c links breast cancer stem cells with normal 
stem cells. Cell 2009, 138:592-603.
13  .  Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K: 
Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated 
repression required for the formation and maintenance of cancer stem 
cells. Mol Cell 2010, 39:761-772.
14  .  Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel 
B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, 
Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T: 
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-
inhibiting microRNAs. Nat Cell Biol 2009, 11:1487-1495.
15 .  Charafe-Jauff  ret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, 
Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, 
Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional 
cancer stem cells with metastatic capacity and a distinct molecular 
signature. Cancer Res 2009, 69:1302-1313.
doi:10.1186/bcr2885
Cite this article as: Radisky DC: miR-200c at the nexus of epithelial–
mesenchymal transition, resistance to apoptosis, and the breast cancer 
stem cell phenotype. Breast Cancer Research 2011, 13:110.
Radisky Breast Cancer Research 2011, 13:110
http://breast-cancer-research.com/content/13/3/110
Page 2 of 2